Skip to main content
TLPH logo

TLPH · Talphera, Inc.

Track TLPH — free
$0.79 +0.05 (+6.25%) At close · Nov 20
Market Cap
$40.80M
Shares
51.96M
Volume · Nov 20 357.32K Avg daily vol (3M) 144.24K

Price & Indicators

 

Key stats

Close
$0.79
Fri 20 Nov
Open
$0.73
Fri 20 Nov
Average volume, 30 days
141K
shares a session
Short interest
1.2M
2.3% of shares · 27.7 days to cover
Day range
$0.72$0.84
Open $0.73 Close $0.79
52-week closing range
$0.72$1.47
Close $0.79 46.6% under the high
Short volume, last session
61%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Mar 22, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 12
Earnings call
FDA may allow study closure with over 80% power

Talphera asked the FDA to close enrollment by December 31, 2026, citing enrollment above 75% and primary-endpoint power above 80%. It expects FDA feedback by year-end, data within four to six weeks, and peak U.S. sales above $200 million.

6 source passages
We recently submitted a briefing document to the FDA requesting a sprint meeting to discuss our proposed approach to closure of the study by December 31, 2026. Enrollment has now exceeded 75% of our plan target, as we reported last quarter. Notably, based on our current enrollment, the study is over 80% powered for the primary endpoint. Based on NIAD's breakthrough device designation, our historical interactions with the FDA, and the statutory timing, we would anticipate feedback will be provided by the end of this year. Hotline data are expected within four to six weeks After enrollment is completed. we have increased our estimate of NIAID's peak annual U.S. sales for use during CRRT to now exceed $200 million. Open the document at this passage
Nov 12
Registration statement S-3
Registers flexible securities shelf for future offerings

Talphera, Inc. may offer up to $150,000,000 of common stock, preferred stock, debt securities and warrants from time to time, with proceeds intended for working capital, general corporate purposes and debt payments.

Read from the first part of this long document
3 source passages
Talphera, Inc. From time to time, we may offer and sell up to an aggregate amount of $150,000,000 of any combination of the securities described in this prospectus, either individually or in combination, at prices and on terms described in one or more supplements to this prospectus. Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital and general corporate purposes, including commercialization activities, general and administrative expenses, research and development expenses, capital expenditures, for making scheduled payments under our debt facility, or any other purpose we describe in the applicable prospectus supplement. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt as losses continue

Talphera reported a net loss of (10,886) in thousands for the nine months ended September 30, 2026; recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.

Revenue $0 Net loss $4.02M
Read from the first part of this long document
4 source passages
Talphera, Inc. Nine Months Ended September 30, | 2026 | 2025 Net loss | (10,886) | (10,518) The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Open the document at this passage
Nov 12
Current report 8-K
FDA feedback sought on early NEPHRO CRRT enrollment closure

Talphera, Inc. seeks FDA feedback on closing NEPHRO CRRT enrollment as of December 31, 2026, even with fewer than 70 patients; enrollment provides more than 80% statistical power. Cash and investments were $14.2 million at September 30, 2026.

Financial results
4 source passages
Talphera, Inc. (Nasdaq: TLPH) (“Talphera”), a specialty pharmaceutical company developing nafamostat as a regional anticoagulant for use in continuous renal replacement therapy (CRRT), today announced financial results for the third quarter of 2026 and provided a business update. Submitted a briefing document to the FDA seeking feedback on a regulatory strategy for a PMA filing based on final NEPHRO CRRT study enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. Talphera’s belief that the current enrollment in the NEPHRO CRRT clinical study which provides more than 80% statistical power for the primary endpoint supports its proposed strategy for an early close of enrollment as of December 31, 2026, subject to FDA’s feedback The cash and investments balance was $14.2 million as of September 30, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$14.66M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.5%
Year over year · more shares
Price change (1Y)
-40.1%
Trailing year
Short interest
2.3%
Latest settlement · 27.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Updated research raised nafamostat's estimated peak CRRT sales to more than $200 million, while current study power supports a potential PMA filing and financing is expected to fund operations through at least a potential 2027 approval. Enrollment has slowed sharply and operating expenses increased; if FDA does not agree to early closure, enrollment would continue to 70 patients, and clinical studies may not be fully enrolled or completed or confirm assumed characteristics.

Bullish
  • + Updated market research increased nafamostat's estimated peak sales for CRRT to more than $200 million. new
  • + Current NEPHRO enrollment is believed sufficient for a PMA filing, with more than 80% statistical power for the primary endpoint. new
  • + Cash and conditional financing tranches are expected to fund the company through at least a potential PMA approval in 2027. new
  • + Clinical-outcomes evidence may support growth of the overall CRRT market. new
  • + Updated draft kidney-disease guidelines recognize nefamostat as an alternative anticoagulant when citrate cannot be used. new
  • + Third-quarter net loss attributable to common shareholders improved to $4.0 million, or $0.05 per share, from $4.4 million, or $0.11 per share. new
Bearish
  • − NEPHRO enrollment has slowed unexpectedly because of fewer qualifying patients. new
  • − The number of patients consented and enrolled dropped 85% to 90% versus the same period in 2025. new
  • − Cash operating expenses increased to $3.8 million from $3.3 million, driven by development and pre-launch preparation spending. new
  • − If the FDA rejects the proposed early closure, enrollment would continue to 70 patients. new
  • − Clinical studies may not be fully enrolled or completed and may not confirm assumed safety or efficacy characteristics. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −26%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 9%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −27%
trailing
6-month return +1%
trailing
YTD return −31%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.35% of shares out · ▲ +14.4% MoM · 27.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
51 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Poor
Revenue growth −73%
Y/Y
EPS growth −123%
Y/Y
Free cash flow $-11.4M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −51%
past year
ATR 10.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
Peak annual U.S. sales from the FAMSTAT in CRRT · peak annual at least $200M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.35% of shares out · ▲ +14.4% MoM · 27.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
51 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 9% Range high $1
vs 200-day avg -22% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Combined R&D and SG&A expenses non-GAAP 3.8M third quarter of 2026 —
Operating expenses (non-GAAP) non-GAAP 11.26M Nine Months Ended September 30, 2026 —
Patients enrolled 75% To date —
Statistical power for primary endpoint 80% To date —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TLPH
Talphera, Inc.
this stock
$40.80M -31.1% -73.1% — 2.3%
TAK
Takeda Pharmaceutical Co Ltd
$69.55B +39.6% — — 0.1%
GALDY
Galderma Group AG
$50.29B +4.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$45.77B +25.7% +4.3% 89.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
51
% held
42.7%
Net QoQ
-1.7M sh
Top holder
AIGH Capital Management L…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
27.7d
Change
+153.0K sh
View
Short Volume
Short vol %
61%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
462
Value
$504
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
71.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.2M
Net income (FY)
$-14.3M
EPS diluted
$-1.29
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
15

Talphera reported a net loss of (10,886) in thousands for the nine months ended September 30, 2026; recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.

View
Proposed Sales
Value
$107
Shares
155
Filed
Dec 2, 2024
View
Exempt Offerings
Offering
$29.0M
Filed
Sep 15, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Talphera Reports Third Quarter 20…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
TLPH -13.3% -27.3% +0.7% -23.8% -31.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.8% -18.1% +9.9% -15.1% -32.3%
Key facts CIK 1427925 CUSIP 00444T209 13F (30d) 57 filings 49 filers Visit website Investor relations